| Literature DB >> 29614664 |
Ríona Mc Ardle1, Rosie Morris1, Aodhán Hickey1, Silvia Del Din1, Ivan Koychev2, Roger N Gunn3,4, Jennifer Lawson2, Giovanna Zamboni2, Basil Ridha5, Barbara J Sahakian6, James B Rowe7, Alan Thomas1, Henrik Zetterberg8,9,10,11, Clare MacKay2, Simon Lovestone2, Lynn Rochesteron1.
Abstract
Gait is emerging as a potential diagnostic tool for cognitive decline. The 'Deep and Frequent Phenotyping for Experimental Medicine in Dementia Study' (D&FP) is a multicenter feasibility study embedded in the United Kingdom Dementia Platform designed to determine participant acceptability and feasibility of extensive and repeated phenotyping to determine the optimal combination of biomarkers to detect disease progression and identify early risk of Alzheimer's disease (AD). Gait is included as a clinical biomarker. The tools to quantify gait in the clinic and home, and suitability for multi-center application have not been examined. Six centers from the National Institute for Health Research Translational Research Collaboration in Dementia initiative recruited 20 individuals with early onset AD. Participants wore a single wearable (tri-axial accelerometer) and completed both clinic-based and free-living gait assessment. A series of macro (behavioral) and micro (spatiotemporal) characteristics were derived from the resultant data using previously validated algorithms. Results indicate good participant acceptability, and potential for use of body-worn sensors in both the clinic and the home. Recommendations for future studies have been provided. Gait has been demonstrated to be a feasible and suitable measure, and future research should examine its suitability as a biomarker in AD.Entities:
Keywords: Alzheimer’s disease; cognition; free-living; gait; phenotyping; wearables
Mesh:
Year: 2018 PMID: 29614664 DOI: 10.3233/JAD-171116
Source DB: PubMed Journal: J Alzheimers Dis ISSN: 1387-2877 Impact factor: 4.472